このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

固形腫瘍の参加者を対象とした単剤療法および抗がん剤との併用療法としてのAZD5335の第I / IIa相試験 (FONTANA)

2026年10月2日 更新者：AstraZeneca

FONTANA: 固形腫瘍の参加者におけるAZD5335単剤療法および抗がん剤との併用療法の漸増用量の安全性、忍容性、薬物動態、および予備的有効性を評価するためのモジュラー第I/IIa相非盲検多施設試験

This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

調査の概要

状態

募集

条件

介入・治療

詳細な説明

This study is a Phase I/IIa modular, open-label, multi-center study of AZD5335 administered either as monotherapy or in combination with other anti-cancer agents in participants with advanced solid malignancies

研究の種類

介入

入学 (推定)

622

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

  • アメリカ
    • California
      • Duarte、California、アメリカ、91010
        • 募集
        • Research Site
      • Irvine、California、アメリカ、92618
        • 募集
        • Research Site
      • La Jolla、California、アメリカ、92093
        • 引きこもった
        • Research Site
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • 募集
        • Research Site
    • Kentucky
      • Louisville、Kentucky、アメリカ、40202
        • 終了しました
        • Research Site
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02114
        • 募集
        • Research Site
    • Michigan
      • Detroit、Michigan、アメリカ、48201
        • 募集
        • Research Site
    • Ohio
      • Columbus、Ohio、アメリカ、43201
        • 募集
        • Research Site
    • Oregon
      • Portland、Oregon、アメリカ、97239
        • 募集
        • Research Site
    • Rhode Island
      • Providence、Rhode Island、アメリカ、02903
        • 募集
        • Research Site
      • Providence、Rhode Island、アメリカ、02905
        • 引きこもった
        • Research Site
    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • Research Site
    • Virginia
      • Fairfax、Virginia、アメリカ、22031
        • 募集
        • Research Site
  • イギリス
      • Cambridge、イギリス、CB2 0XY
        • 募集
        • Research Site
      • Glasgow, Scotland、イギリス、G12 0YN
        • 募集
        • Research Site
      • London、イギリス、SE1 9RT
        • まだ募集していません
        • Research Site
      • London、イギリス、SW3 6JJ
        • 募集
        • Research Site
      • Sutton、イギリス、SM2 5PT
        • 募集
        • Research Site
  • イスラエル
      • Haifa、イスラエル、3109601
        • 募集
        • Research Site
      • Ramat Gan、イスラエル、52621
        • 募集
        • Research Site
  • オーストラリア
      • Liverpool、オーストラリア、2170
        • 募集
        • Research Site
      • Melbourne、オーストラリア、3000
        • 募集
        • Research Site
  • カナダ
    • Alberta
      • Edmonton、Alberta、カナダ、T6G 1Z2
        • 募集
        • Research Site
    • Ontario
      • London、Ontario、カナダ、N6A 5W9
        • 募集
        • Research Site
      • Toronto、Ontario、カナダ、M5G 2M9
        • 募集
        • Research Site
    • Quebec
      • Montreal、Quebec、カナダ、H4A 3J1
        • 募集
        • Research Site
      • Montreal、Quebec、カナダ、H2X 0A9
        • 募集
        • Research Site
  • スペイン
      • Barcelona、スペイン、8035
        • 募集
        • Research Site
      • Madrid、スペイン、28041
        • 募集
        • Research Site
      • Madrid、スペイン、28050
        • 募集
        • Research Site
      • Málaga、スペイン、29010
        • 募集
        • Research Site
  • トルコ（Türkiye）
      • Ankara、トルコ（Türkiye）、06800
        • 募集
        • Research Site
      • Ankara、トルコ（Türkiye）、06050
        • 募集
        • Research Site
      • Ankara、トルコ（Türkiye）、06200
        • 募集
        • Research Site
      • Istanbul、トルコ（Türkiye）、34718
        • 募集
        • Research Site
  • ドイツ
      • Berlin、ドイツ、13353
        • 募集
        • Research Site
      • Essen、ドイツ、45136
        • 募集
        • Research Site
      • Freiburg im Breisgau、ドイツ、79106
        • 募集
        • Research Site
      • Hanover、ドイツ、30625
        • 募集
        • Research Site
      • Leipzig、ドイツ、04103
        • 募集
        • Research Site
      • Mannheim、ドイツ、68167
        • 募集
        • Research Site
      • Regensburg、ドイツ、93053
        • 募集
        • Research Site
  • 中国
      • Chengdu、中国、610041
        • 募集
        • Research Site
      • Chongqing、中国、400030
        • 募集
        • Research Site
      • Guangzhou、中国、510060
        • 募集
        • Research Site
      • Guangzhou、中国、510000
        • 募集
        • Research Site
      • Jinan、中国、250117
        • 募集
        • Research Site
      • Xi'an、中国、710061
        • 募集
        • Research Site
      • Zhengzhou、中国、450008
        • 終了しました
        • Research Site
  • 台湾
      • Taichung、台湾、40705
        • 募集
        • Research Site
      • Tainan、台湾、70403
        • 募集
        • Research Site
      • Taipei、台湾、10002
        • 募集
        • Research Site
      • Taipei、台湾、11259
        • 募集
        • Research Site
  • 日本
      • Hidaka-shi、日本、350-1298
        • 募集
        • Research Site
      • Kashiwa、日本、227-8577
        • 募集
        • Research Site
      • Kōtoku、日本、135-8550
        • 募集
        • Research Site
      • Sunto-gun、日本、411-8777
        • 募集
        • Research Site
      • Tokyo、日本、104-0045
        • 募集
        • Research Site
  • 韓国
      • Seoul、韓国、03080
        • 募集
        • Research Site
      • Seoul、韓国、06351
        • 募集
        • Research Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年～130年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Core Inclusion Criteria:

  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

  • Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples for optional genetic research that supports Genomic Initiative. Participants who do not provide informed consent for Optional Genetic Research may still be enrolled in the study.

  • Participant must be ≥ 18 years at the time of signing the informed consent.

  • Willing to provide adequate archival and/or baseline tumor sample as applicable per module-specific criteria.

  • For participants who have previously received targeted therapies such as ADCs, a fresh baseline biopsy will be required unless the most recent archival tissue sample was collected after receipt of such treatment.

  • Eastern Cooperative Oncology Group Performance Status of 0 or 1.

  • Participants with advanced solid tumors must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease, or, in the opinion of the Investigator, a clinical trial is the best option for the next treatment based on response and/or tolerability to prior therapy. Participants with contraindications or who refuse therapy in accordance with local practice may also be considered provided that it is documented that he/she was informed about all therapeutic options.

  • Participants must have measurable disease per RECIST v1.1,

    1. A previously irradiated lesion can be considered a target lesion if the lesion is progressing and well defined.
    2. For participants who undergo biopsies at screening and/or on treatment, it is preferred though not required, that the biopsied lesion, be distinct from any target lesion used in the RECIST v1.1 evaluation.

  • Life expectancy ≥ 12 weeks.

  • Adequate organ and marrow function.

  • Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    (a) Male participants: (i) Male participants who are sexually active with a female partner of childbearing potential must use a male condom (plus an additional contraceptive method) post-screening for at least 8 months following the last dose of study intervention. It is strongly recommended for the female partner of a male participant to also use a highly effective method of contraception throughout this period. In addition, male participants must refrain from freezing or donating sperm while on study and for 8 months following the last dose of study intervention.

    (b) Female participants : (i) Females of childbearing potential must have a negative serum pregnancy test result within 72 hours prior to receiving the first dose of study intervention and a negative urine or serum pregnancy test prior to starting their next cycle of treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

(ii) (ii) Sex and Contraceptive/Barrier Requirements: Highly effective birth control methods include: Total sexual abstinence is an acceptable method provided it is the usual lifestyle of the participant (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments) [(periodic abstinence e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of exposure to study intervention, and withdrawal are not acceptable methods of contraception], a vasectomized partner, Implanon®, bilateral tubal occlusion, intrauterine device/levonorgestrel intrauterine system, Depo Provera™ injections, oral contraceptive associated with inhibition of ovulation, and Evra Patch™, Xulane™, or NuvaRing®.

Female participants of childbearing potential who are sexually active with a non-sterilized male partner must agree to use one highly effective method of birth control (defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly), from enrolment throughout the study and for 8 months following the last dose of study intervention. The male partner of a female participant of childbearing potential must also use a male condom (plus spermicide, if available) throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. In addition, female participants must not donate or retrieve for their own use, ova while on study and for 8 months following the last dose of study intervention.

Core Exclusion Criteria:

  • Patients with spinal cord compression or a history of leptomeningeal carcinomatosis.
  • Patients with brain metastases unless, asymptomatic, stable, and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to first dose of study intervention.
  • Treatment with any of the protocol defined medications, without adequate washout periods or time before the first dose of study intervention.
  • Unresolved toxicities of Grade ≥ 2 (National Cancer Institute [NCI] CTCAE v5.0) from prior therapy (excluding vitiligo, alopecia, and endocrine disorders that are controlled with replacement hormone therapy). Participants with stable ≤ Grade 2 neuropathy are eligible.
  • Active infection, including tuberculosis and infections with hepatitis B virus (HBV; verified by known positive hepatitis B surface antigen [HBsAg] result), hepatitis C virus (HCV) or known HIV infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, CD4+ count ≥ 350/mm3, no history of acquired immune deficiency syndrome-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen).

Patients with a past or resolved HBV/HCV infection are eligible if:

  1. Negative for HBsAg and positive for anti-hepatitis B virus core protein (HBc) or
  2. Are HBsAg + with chronic HBV infection (lasting 6 months or longer) and meet conditions i-iii below:

(i) HBV DNA viral load <100 IU/mL. (ii) Have normal transaminase values, or, if liver metastases are present, abnormal transaminases, with a result of aspartate aminotransferase (AST)/alanine aminotransferase (ALT) <3 x upper limit of normal (ULN), which are not attributable to HBV infection.

(iii) Start or maintain antiviral treatment if clinically indicated as per the Investigator or as per local guideline.

Note for Japan: Japanese patients with positive anti-HBs/anti-HBc and negative HBsAg will be assessed following local guidelines.

(c) Participants testing positive for HCV antibody are eligible only if the polymerase chain reaction test result is negative for HCV RNA.

  • Patient has active ILD/pneumonitis or has a history of (non-infectious) ILD/pneumonitis that required oral or IV steroids or supplemental oxygen, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.

    • Patients with a history of radiation pneumonitis which has clinically and radiologically resolved and not requiring treatment with steroids may be eligible.

  • History of another malignancy except for:

    • Malignancy treated with curative intent and with no known active disease for at least 2 years prior to screening of study intervention and with low potential risk for recurrence.
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated carcinoma in situ without evidence of disease.
    • Localized non-invasive solid organ primary disease under surveillance.

  • Patients with any of the following cardiac criteria:

    • History of arrhythmia (such as multifocal premature ventricular contractions, bigeminy, trigeminy, and ventricular tachycardia), which is symptomatic or requires treatment NCI CTCAE v5.0 Grade 3 except for:

      (i) Rate controlled asymptomatic atrial fibrillation.

      • NOTE: significant abnormalities in serum electrolytes that can increase the risk of arrhythmic events (ie, sodium, potassium, calcium, and magnesium) should be corrected before starting the study intervention.

    • Uncontrolled hypertension.

    • Acute coronary syndrome/acute myocardial infarction, unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention, or coronary artery bypass grafting within 6 months of screening.

    • History of brain perfusion problems (eg, carotid stenosis) or stroke, or transient ischemic attack in the last 6 months prior to screening.

    • Symptomatic heart failure (as defined by New York Heart Association class ≥ 2).

    • Prior or current diagnosis of cardiomyopathy considered clinically relevant per investigator's judgement.

    • Severe uncorrected valvular heart disease.

    • Mean resting QTcF > 470 msec obtained from triplicate electrocardiograms (ECGs) and averaged, recorded within 5 minutes.

    • Any factor that, in the opinion of the investigator, increases the proarrhythmic risk of QT prolongation, such as congenital long QT syndrome, family history of long QT syndrome, hypertrophic cardiomyopathy, or unexplained sudden cardiac death under 40 years of age.

  • Uncontrolled and/or unresolved intercurrent illness within 12 months prior to screening, including but not limited to serious chronic gastrointestinal conditions associated with diarrhea, or illness (including psychiatric illness) and/or social situations, in the opinion of the investigator, that would limit compliance with study requirements and activities, substantially increase risk of incurring AEs or compromise the ability of the participant to give written informed consent.

  • Substance abuse or any other medical conditions that would increase the safety risk to the participant or interfere with participation of the participant or evaluation of the clinical study in the opinion of the Investigator.

  • Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention. Note: Participants, if enrolled, should not receive live vaccine whilst receiving study intervention and up to 3 months after the last dose of study intervention. Participants can receive Coronavirus (COVID)-19 vaccines, at the discretion of the Investigator, following a benefit/risk evaluation for the individual participant and in accordance with local rules and regulations and vaccination guidelines. Note: If a COVID-19 vaccine is administered it should be done > 72 hours prior to study intervention initiation or after completion of the DLT period.

  • For women only - currently pregnant (confirmed with positive pregnancy test or suspected), lactating, breastfeeding, or intention to become pregnant during the study period.

  • Concurrent enrolment in another clinical study, unless it is an observational (non interventional) clinical study or during the follow-up period of an interventional study. Exception: Diagnostic imaging evaluation studies (e.g. PET) may be allowed subject to case-by-case discussion with the Sponsor.

  • Patients with a known hypersensitivity to study intervention or any of the excipients of the product.

  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).

  • Judgment by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

  • Previous enrolment in the present study. **Other module specific criteria may apply

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：処理
  • 割り当て：ランダム化
  • 介入モデル：順次割り当て
  • マスキング：なし（オープンラベル）

武器と介入

参加者グループ / アーム
介入・治療
実験的：Module 1: Torvu-sam Monotherapy

Torvu-sam Monotherapy
薬：Torvutatug samrotecan

IV Antibody-drug conjugate

他の名前：
  • Torvu-sam, AZD5335
実験的：Module 2: Torvu-sam + Saruparib

Torvu-sam + Saruparib
薬：Torvutatug samrotecan

IV Antibody-drug conjugate

他の名前：
  • Torvu-sam, AZD5335
薬：Saruparib

Oral PARP inhibitor

他の名前：
  • AZD5305
実験的：Module 3: Torvu-sam + Bevacizumab

Torvu-sam + Bevacizumab
薬：Torvutatug samrotecan

IV Antibody-drug conjugate

他の名前：
  • Torvu-sam, AZD5335
薬：Bevacizumab

IV Monoclonal antibody

他の名前：
  • アバスチン
実験的：Module 4: Torvu-sam + Carboplatin +/- Bevacizumab

Torvu-sam + Carboplatin +/- Bevacizumab
薬：Torvutatug samrotecan

IV Antibody-drug conjugate

他の名前：
  • Torvu-sam, AZD5335
薬：Bevacizumab

IV Monoclonal antibody

他の名前：
  • アバスチン
薬：Carboplatin

IV Alkylating agent

他の名前：
  • パラプラチン
実験的：Module 5: Torvu-sam + Palacaparib +/- Bevacizumab

Torvu-sam + Palacaparib +/- Bevacizumab
薬：Torvutatug samrotecan

IV Antibody-drug conjugate

他の名前：
  • Torvu-sam, AZD5335
薬：Bevacizumab

IV Monoclonal antibody

他の名前：
  • アバスチン
薬：Palacaparib

Oral PARP inhibitor

他の名前：
  • AZD9574
実験的：Module 6: Torvu-sam + Pembrolizumab +/- Palacaparib

Torvu-sam + Pembrolizumab +/- Palacaparib
薬：Torvutatug samrotecan

IV Antibody-drug conjugate

他の名前：
  • Torvu-sam, AZD5335
薬：Palacaparib

Oral PARP inhibitor

他の名前：
  • AZD9574
薬：Pembrolizumab

IV Biologic

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of participants with adverse events/serious adverse events
時間枠：From time of Informed Consent to 30 days post last dose.

Number of participants with incidence of adverse events and with serious adverse events including changes from baseline in laboratory parameters, vital signs, ECGs, and physical examination.
From time of Informed Consent to 30 days post last dose.
The number of participants with dose limiting toxicity(DLT), as defined in the protocol
時間枠：From the first dose of torvu-sam on Cycle 1 Day 1 up to and including the planned end of Cycle 1 (At the end of 21 days)

A DLT is defined as any ≥ Grade 3 treatment-emergent AE that occurs during the DLT evaluation period, not attributable to the underlying disease or extraneous causes (as defined in the protocol)
From the first dose of torvu-sam on Cycle 1 Day 1 up to and including the planned end of Cycle 1 (At the end of 21 days)

二次結果の測定

結果測定
メジャーの説明
時間枠
Objective Response Rate (ORR)
時間枠：From time of Informed Consent to progressive disease or withdrawal of consent.(approx 2 years)

The percentage of participants with a confirmed CR or PR according to RECIST v1.1 criteria.
From time of Informed Consent to progressive disease or withdrawal of consent.(approx 2 years)
Duration of Response (DoR)
時間枠：From the first documented response to confirmed progression or death in the absence of disease progression.(approx 2 years)

The time from the date of first response until date of disease progression or death in the absence of disease progression.
From the first documented response to confirmed progression or death in the absence of disease progression.(approx 2 years)
Disease Control Rate (DCR)
時間枠：From time of Informed Consent until progression.(approx 15 weeks)

The percentage of participants who have a best objective response of confirmed CR or PR or who have SD for at least 15 weeks after start of treatment (to allow for an early assessment within the assessment window).
From time of Informed Consent until progression.(approx 15 weeks)
Progression free Survival (PFS)
時間枠：From time of first dose of torvu-sam or anti-cancer study agent until the date of objective disease progression or death (by any cause in the absence of progression) (approx 2 years)

Progression-free survival is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participant withdraws from assigned therapy or receives another anti-cancer therapy prior to progression. Participants who have not progressed or died at the time of analysis will be censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment
From time of first dose of torvu-sam or anti-cancer study agent until the date of objective disease progression or death (by any cause in the absence of progression) (approx 2 years)
Overall Survival (OS)
時間枠：From time of first dose of torvu-sam or anti-cancer study agent until death due to any cause (approx 2 years)

The time until death due to any cause.
From time of first dose of torvu-sam or anti-cancer study agent until death due to any cause (approx 2 years)
Module 1: Pharmacokinetics of torvu-sam
時間枠：From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approx 12 weeks) through 30-day follow-up

The plasma concentrations of torvu-sam, total antibody, and total unconjugated payload.
From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approx 12 weeks) through 30-day follow-up
Module 1: Pharmacokinetics of torvu-sam: Area Under the concentration-time curve(AUC)
時間枠：From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approximately 12 weeks) through 30-day follow-up

Area under the plasma concentration-time curve
From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approximately 12 weeks) through 30-day follow-up
Module 1: Pharmacokinetics of torvu-sam: Maximum plasma concentration of the study drug (Cmax)
時間枠：From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approximately 12 weeks) through 30-day follow-up

Maximum observed plasma concentration of the study drug
From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approximately 12 weeks) through 30-day follow-up
Module 1: Pharmacokinetics of torvu-sam: Time to maximum plasma concentration of the study drug (T-max)
時間枠：From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approximately 12 weeks) through 30-day follow-up

Time to maximum observed plasma concentration of the study drug
From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approximately 12 weeks) through 30-day follow-up
Module 1: Pharmacokinetics of torvu-sam: Clearance
時間枠：From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approximately 12 weeks) through 30-day follow-up

A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time.
From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approximately 12 weeks) through 30-day follow-up
Module 1: Pharmacokinetics of torvu-sam: Terminal elimination half-life (t 1/2)
時間枠：From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approximately 12 weeks) through 30-day follow-up

Terminal elimination half-life.
From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approximately 12 weeks) through 30-day follow-up
Module 1: To investigate baseline and on treatment changes in target expression.
時間枠：Baseline and predicted intervals throughout the administration of torvu-sam (approx 2 years)

The clinical activity by baseline and on-treatment changes in tumor target expression.
Baseline and predicted intervals throughout the administration of torvu-sam (approx 2 years)
Module 2: Pharmacokinetics of torvu-sam and saruparib when given in combination.
時間枠：From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam and saruparib (approx 12 weeks) through 30-day follow-up

The plasma concentrations of torvu-sam, total antibody, and total unconjugated payload.
From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam and saruparib (approx 12 weeks) through 30-day follow-up
Module 3: Pharmacokinetics of torvu-sam and bevaczizumab when given in combination.
時間枠：From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam and bevacizumab (approx 12 weeks) through 30-day follow-up

The plasma concentrations of torvu-sam, total antibody, and total unconjugated payload.
From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam and bevacizumab (approx 12 weeks) through 30-day follow-up
Module 4: Pharmacokinetics of torvu-sam and carboplatin (+/- bevacizumab) when given in combination.
時間枠：From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam and carboplatin (+/- bevacizumab) (approx 12 weeks) through 30-day follow-up

The plasma concentrations of torvu-sam, total antibody, and total unconjugated payload.
From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam and carboplatin (+/- bevacizumab) (approx 12 weeks) through 30-day follow-up
Module 5: Pharmacokinetics of torvu-sam and palacaparib (+/- bevacizumab) when given in combination.
時間枠：From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam and palacaparib (+/- bevacizumab) (approx 12 weeks) through 30-day follow-up

The plasma concentrations of torvu-sam, total antibody, and total unconjugated payload.
From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam and palacaparib (+/- bevacizumab) (approx 12 weeks) through 30-day follow-up
Module 6: Pharmacokinetics of torvu-sam and pembrolizumab (+/- palacaparib) when given in combination.
時間枠：From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam and pembrolizumab (+/- palacaparib).(approx 12 weeks) through 90-day follow-up

The plasma concentrations of torvu-sam, total antibody, and total unconjugated payload.
From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam and pembrolizumab (+/- palacaparib).(approx 12 weeks) through 90-day follow-up
Module 2, 3, 4, 5, and 6: Area Under the concentration-time curve (AUC)
時間枠：At predefined intervals throughout the treatment period (approximately 12 weeks)

Area under the plasma concentration-time curve
At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 2, 3, 4, 5, and 6: Maximum plasma concentration of the study drug (Cmax)
時間枠：At predefined intervals throughout the treatment period (approximately 12 weeks)

Maximum observed plasma concentration of the study drug
At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 2, 3, 4, 5, and 6: Time to maximum plasma concentration of the study drug (T-max)
時間枠：At predefined intervals throughout the treatment period (approximately 12 weeks)

Time to maximum observed plasma concentration of the study drug
At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 2, 3, 4, 5, and 6: Clearance
時間枠：At predefined intervals throughout the treatment period (approximately 12 weeks)

A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time.
At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 2, 3, 4, 5, and 6: Terminal elimination half-life (t 1/2)
時間枠：From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approximately 12 weeks)

Terminal elimination half-life.
From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approximately 12 weeks)
Immunogenicity of torvu-sam
時間枠：From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approx 2 years) through 30-day follow-up

The number and percentage of participants who develop ADAs.
From the first dose of study intervention, at predefined intervals throughout the administration of torvu-sam (approx 2 years) through 30-day follow-up

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

AstraZeneca

捜査官

  • 主任研究者：Funda Meric-Bernstam, MD、UT MD Anderson Cancer Center

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年6月5日

一次修了 (推定)

2028年8月4日

研究の完了 (推定)

2028年8月4日

試験登録日

最初に提出

2023年2月21日

QC基準を満たした最初の提出物

2023年3月21日

最初の投稿 (実際)

2023年4月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年10月2日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • D8990C00001
  • 2022-502576-23-00 (レジストリ識別子：CTIS (EU))

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD 共有時間枠

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共有アクセス基準

When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する